Bruker Corporation (BRKR) Stock Price & Analysis
Bruker Corporation (BRKR) closed at USD 57.31 on Thursday, October 22, 2026, down 3.04% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 57.31; the Oct 22, 2026 session ranged USD 55.53–60.65 on volume of 2,371,610 shares. Market capitalization is —, with a 52-week range of USD 32.37–66.98 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:28 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BRKR.md
Key facts (BRKR)
- Last four reported quarters (through Jun 30, 2026): revenue $3.50B, net income -$71.2M (-2.0% margin), free cash flow $93.9M (SEC filings).
- 2 of 80 tracked superinvestors hold BRKR (13F, Q3 2025 (1 investor on Q2 2026, filed early)): 1 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $816K; 1 not under a Rule 10b5-1 plan ($198K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.54 on a 1–5 scale) (13 analysts), mean target USD 63.83 (range 50–80).
- Total return with dividends: 1Y +44.9% vs S&P 500 +14.9%; 5Y -25.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 0.42, revenue estimate $865M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BRKR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.42B | $2.53B | $2.96B | $3.37B | $3.44B | $3.50B |
| Gross profit | $1.21B | $1.31B | $1.51B | $1.65B | $1.58B | — |
| Operating income | $413M | $433M | $437M | $253M | $68.2M | -$30.6M |
| Net income | $277M | $297M | $427M | $113M | -$8.6M | -$71.2M |
| EPS (diluted) | $1.81 | $1.99 | $2.90 | $0.76 | -$0.15 | — |
| Free cash flow | $190M | $145M | $243M | $136M | $43.3M | $93.9M |
| Gross margin | 50.0% | 51.6% | 51.0% | 49.0% | 45.9% | — |
| Operating margin | 17.1% | 17.1% | 14.7% | 7.5% | 2.0% | -0.9% |
| Net margin | 11.5% | 11.7% | 14.4% | 3.4% | -0.3% | -2.0% |
| Revenue growth | +21.7% | +4.7% | +17.1% | +13.6% | +2.1% | — |
| Cash + short-term investments | $1.17B | $646M | — | — | $299M | — |
| Total debt | $1.33B | $1.22B | $1.28B | $2.09B | $1.87B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BRKR)
P/E at fiscal year-ends: Dec 2024 77.5x, Dec 2023 25.3x.
Superinvestors (SEC 13F-HR, Q3 2025) (BRKR)
2 of 80 tracked investors hold BRKR (1 investor on Q2 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Michael Burry | Scion Asset Management | 19.28% | $13.1M | Reduced -80.7% | Q3 2025 |
| Viking Global | Viking Global Investors | 0.15% | $53.8M | New position | Q2 2026 |
Insider sales (SEC Form 4, open-market, last ~7 months) (BRKR)
6 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2,000 | $106K | 1.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-08-17 | Pusch Wolfgang | President BMID Group | 3,473 | $198K | 26.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-14 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2,000 | $115K | 1.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-15 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2,000 | $121K | 1.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-15 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2,000 | $110K | 1.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-15 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2,000 | $88K | 1.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-04-15 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | 2,000 | $80K | 1.5% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BRKR)
Consensus Hold (mean 2.54 on a 1–5 scale), 13 analysts; mean target USD 63.83 (low 50, high 80).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | JP Morgan | Downgrade | Overweight → Neutral | $60 |
| 2026-10-13 | TD Cowen | Target raised | Hold | $60 → $62 |
| 2026-10-07 | Barclays | Target raised | Overweight | $58 → $70 |
| 2026-10-01 | Guggenheim | Target raised | Buy | $70 → $72 |
| 2026-09-29 | Leerink Partners | Target raised | Outperform | $60 → $80 |
| 2026-09-09 | UBS | Target raised | Neutral | $45 → $65 |
| 2026-08-05 | Citigroup | Target lowered | Neutral | $60 → $53 |
| 2026-07-08 | Citigroup | Target raised | Neutral | $44 → $60 |
| 2026-07-07 | Leerink Partners | Target raised | Outperform | $60 → $70 |
| 2026-06-29 | Guggenheim | Target raised | Buy | $50 → $70 |
Total return (dividends reinvested) (BRKR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +44.9% | -25.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +45.1% | -5.7% |
| Volatility (annualized) | 57.3% | 43.8% |
| Max drawdown | -39.9% (Jan 2026→Mar 2026) | -67.5% (Mar 2024→Aug 2025) |
Companies that name BRKR in their SEC reports
| Relationship to BRKR | Company | Filing | Sentence |
|---|---|---|---|
| partner | GLOBAL PARTNERS LP (GLP) | 10-K Feb 27, 2026 | “At Ernst & Young, Mr. Pereira was responsible for the Consumer Products practice in the Northeast Region and was the coordinating partner for Global Partners LP and other clients such as Bruker Corporation and Au Bon Pain.” |
| customer | VERACYTE, INC. (VCYT) | 10-K Feb 26, 2026 | “For example, we rely on NanoString (now Bruker Spatial Biology as a result of Bruker Corporation's asset acquisition of NanoString) for certain components and raw materials for the Prosigna test and nCounter service kits.” |
BRKR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.42 | $0.55 | -24.5% | $865.2M | 12 |
| Next quarter (ends Dec 2026) | $0.90 | $0.87 | +3.3% | $1.03B | 12 |
| Current fiscal year (ends Dec 2026) | $2.12 | $2.12 | +0.0% | $3.56B | 13 |
| Next fiscal year (ends Dec 2027) | $2.40 | $2.43 | -1.1% | $3.70B | 13 |
Key Statistics (as of October 23, 2026 at 09:28 UTC)
| Price | USD 57.31 |
|---|---|
| Change | ▼ 3.04% (down) |
| Previous Close | USD 57.31 |
| Open | USD 57.31 |
| Day Range | USD 55.53 – 60.65 |
| 52-Week Range | USD 32.37 – 66.98 |
| Volume | 2,371,610 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (BRKR)
Nexqual's technical model rates BRKR "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:28 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.21 (neutral) |
| vs SMA50 | Below (USD 58.72) |
| MACD | -0.87 (negative) |
Analyst Ratings (BRKR)
Wall Street analysts rate BRKR "Hold" based on 13 analysts, with a mean price target of USD 63.83 (range USD 50–80), per Nexqual as of October 23, 2026 at 09:28 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 63.83 |
| High Target | USD 80 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 6 / 6 / 1 |
Earnings (BRKR)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.42 |
| Revenue Estimate | $865.19M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.49 vs est 0.38 ▲ beat |
| 2026-03-31 | USD 0.31 vs est 0.23 ▲ beat |
| 2025-12-31 | USD 0.59 vs est 0.65 ▼ miss |
| 2025-09-30 | USD 0.45 vs est 0.32 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Financials & Fundamentals (BRKR)
| Total Revenue | $3.50B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.20% |
| Gross Margin | +48.48% |
| Operating Margin | +9.88% |
| Profit Margin | -2.04% |
| ROE | -3.00% |
| Debt / Equity | 0.76 |
| Current Ratio | 1.85 |
| Total Cash | $184.90M |
| Total Debt | $1.86B |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Ownership (BRKR)
| Insider Ownership | +26.97% |
|---|---|
| Institutional Ownership | +95.57% |
| Shares Outstanding | 152.36M |
| Float | 103.69M |
| Short % of Float | +15.69% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIO-B | Bio-Rad Laboratories, Inc. | USD 364.15 | ▼ 0.25% |
| PODD | Insulet Corporation | USD 148.12 | ▲ 4.38% |
| TXG | 10x Genomics, Inc. | USD 69.75 | ▼ 7.73% |
| GKOS | Glaukos Corporation | USD 176.69 | ▼ 0.09% |
| GMED | Globus Medical, Inc. | USD 81.66 | ▲ 3.79% |
| SNN | Smith & Nephew SNATS, Inc. | USD 30.88 | ▲ 5.64% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:28 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt